Source comparison
MK-677 Injection Pain: Injectable vs Oral Comparison
Bioavailability 95–100% (bypasses first-pass metabolism) 60–75% (hepatic metabolism reduces plasma concentration) Injectable form delivers 25–40% more active compound per mg administered. Meaningful for dose-sensitive protocols Onset Time 15–30 minutes to peak
This comparison does not assign a generated winner or score.
- Bioavailability
- 95–100% (bypasses first-pass metabolism)
- 60–75% (hepatic metabolism reduces plasma concentration)
- Injectable form delivers 25–40% more active compound per mg administered. Meaningful for dose-sensitive protocols
- Onset Time
- 15–30 minutes to peak plasma levels
- 60–90 minutes to peak plasma levels
- Injectable onset is 3–4× faster, relevant for users timing administration around training or sleep
- Administration Discomfort
- Moderate (pH-dependent sting, technique-sensitive)
- None (oral administration)
- Oral wins on comfort. But injectable discomfort is nearly eliminated with proper reconstitution and slow injection
- Dosing Precision
- Exact (measured in syringe graduations)
- Variable (tablet splitting, capsule content variation)
- Injectable allows 0.1 mg precision; oral dosing accuracy depends on manufacturer and user technique
- Cost per Dose
- $2.50–$4.00 (lyophilized peptide + bacteriostatic water)
- $1.50–$2.50 (tablet or capsule)
- Oral is 30–40% cheaper per dose, but injectable's higher bioavailability narrows the cost-per-active-mg gap
- Storage Requirements
- Refrigeration required (2–8°C for reconstituted solution)
- Room temperature stable (tablets/capsules)
- Oral wins on convenience. Injectable requires cold chain and sterile handling